CCL15: A Potential Drug Target for Various Diseases (G6359)
CCL15: A Potential Drug Target for Various Diseases
CCL15 (LKN-1), a cell surface glycoprotein, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure, which consists of a N-terminal extracellular domain, a transmembrane domain , and an C-terminal cytoplasmic domain, making it an attractive target for small molecules.
CCL15 is a protein that is expressed in various tissues and cells, including the brain, spinal cord, peripheral nerves, and various types of cancer cells. Its function in different cell types is still not well understood, but research has shown that it plays a role in various physiological processes, including cell adhesion, migration, and invasion.
One of the key functions of CCL15 is its role in cell adhesion. CCL15 is a member of the Integrin伪6 subfamily of cytoskeletal proteins, which are involved in the formation of tight junctions and adherens junctions, which are essential for maintaining tissue structure and function. Research Show that CCL15 plays a critical role in the formation of these tight junctions and adherens junctions, and its absence has been implicated in the development of various diseases, including cancer.
Another function of CCL15 is its role in cancer progression. CCL15 has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis, which are critical processes in cancer development. For example, studies have shown that CCL15 can promote the growth and survival of cancer cells, and its inhibition has been shown to inhibit the development of cancer.
In addition to its role in cancer, CCL15 has also been implicated in the development of neurodegenerative disorders. As mentioned earlier, CCL15 is involved in the formation of tight junctions and adherens junctions, which are important for maintaining the integrity of the blood-brain barrier . The loss of these tight junctions and adherens junctions has been implicated in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.
Furthermore, CCL15 has also been shown to be involved in the regulation of autoimmune diseases. CCL15 has been shown to play a role in the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that CCL15 can activate immune cells and trigger an autoimmune response, which can lead to the development of these diseases.
In conclusion, CCL15 is a protein that has been shown to play a critical role in a variety of biological processes, including cell adhesion, cancer progression, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an attractive target for small molecules , and its potential as a drug or biomarker makes it a valuable tool for the development of new treatments for these diseases.
CCL15 has been shown to play a role in the regulation of cell adhesion, and its inhibition has been shown to have therapeutic potential in a variety of diseases. For example, studies have shown that CCL15 can promote the growth and survival of cancer cells, and Its inhibition has been shown to inhibit the development of cancer. This suggests that CCL15 may be a useful target for cancer therapies that target cell adhesion.
In addition to its role in cancer, CCL15 has also been implicated in the development of neurodegenerative disorders. The loss of tight junctions and adherens junctions, which are important for maintaining the integrity of the blood-brain barrier, has been implicated in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Therefore, CCL15 may be
Protein Name: C-C Motif Chemokine Ligand 15
Functions: Chemotactic factor that attracts T-cells and monocytes, but not neutrophils, eosinophils, or B-cells. Acts mainly via CC chemokine receptor CCR1. Also binds to CCR3. CCL15(22-92), CCL15(25-92) and CCL15(29-92) are more potent chemoattractants than the CCL15
The "CCL15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL15 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7
